| |
Epigenetics Therapeutics to 2017
Four Epigenetics Drugs Generated Revenues of $517m in 2009
|
|
| |
Hyderabad,
AP,
India
(PRBD.net)
8/26/2010 12:00:00 AM
-
Vidaza, Dacogen, Zolinza and Istodax are the four currently approved epigenetic drugs in the market. The sales of these drugs amounted to $517m in 2009. Vidaza and Dacogen are approved for the indication Myelodysplastic Syndrome (MDS) and Zolinza and Istodax are approved for the indication Cutaneous T-cell lymphoma (CTCL). Of all the drugs, Vidaza had the largest market share in 2009, followed by Dacogen.
Vidaza and Dacogen belong to a new class of drugs called DNA Methyltransferase inhibitors. These drugs cause the removal of the methyl group from the cytosine residue in the DNA and cause the repression of tumor genes. Of all the drugs, Vidaza and Dacogen are the most commonly used drugs for the treatment of MDS. They are currently employed by physicians as a second or third line of therapy.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Epigenetics-Novel-Approaches-in-Prognosis-Diagnosis-and-Treatment-of-Chronic-Diseases&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Vidaza is in the late stage of clinical trials for the treatment of Acute Myeloid Leukemia (AML). AML is a rare disease that affects the blood cells. As Vidaza is approved for MDS, which is a precursor to AML, it is expected to be widely accepted after being approved for AML. Vidaza is estimated to achieve peak sales of $312m for AML by the year 2012 in the top seven markets.
Dacogen by Eisai is similar to Vidaza in terms of its mechanism of action and is indicated for the treatment of MDS. The annual cost of Dacogen treatment for MDS is $61,938, which is higher than Vidaza’s cost. Dacogen is employed as an alternative to Vidaza therapy in many cases, which leads to lower uptake. Thus, Dacogen is forecast to reach revenues of $283m by 2017, which is much lower than the estimates for Vidaza.
Zolinza is indicated for the treatment CTCL which is a rare disease. The market for Zolinza as a CTCL therapy is expected to be steady throughout the forecast period. The annual cost of treatment ranges from $25,743 to $31,464 depending on the treatment period. The increase in the incidence and prevalence of the disease will drive the market from $21m in 2009 to $42m in 2017 at a Compound Annual Growth Rate (CAGR) of 10.7%.
GBI Research, a leading business intelligence provider, has released its latest research, “Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma.” The report provides insights on segments where epigenetic therapies may prove to be useful. The report also details the market potential for the epigenetic therapies, Furthermore, it provides insights into the epigenetic therapeutics R&D pipeline. The report also contains comprehensive profiles of the epigenetic therapies in late-stage clinical development. The report offers insights into the US, the top five markets in Europe and Japan. The report also elucidates the current competitive landscape of the epigenetic therapeutics market.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Epigenetics-Novel-Approaches-in-Prognosis-Diagnosis-and-Treatment-of-Chronic-Diseases&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.gbiresearch.com
For more details Contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
|
|
|
|
Contact Information
Rajesh Gunnam
GlobalData
e-park, hyderabad
Hyderabad,
AP,
500050
India
91-40661-66782
rgunnam@globaldata.com
Visit Our Site
|
Get your Press release distributed to 90+ PR directories and 100’s of Journalists.
FREE featured news at PRBD.NET, PR4links.com and Sardnews.org worth $27.
|
|
|
|
|